Adenocarcinoma de Próstata: Qué Es y Cómo se Trata

Prostate adenocarcinoma is a cancer that arises from the glandular cells lining the prostate, and it accounts for the vast majority of prostate cancer diagnoses. How it behaves and how it is treated vary enormously depending on how aggressive the tumor is and whether it has spread beyond the gland. Some men with low-grade disease live decades without treatment, monitored through periodic check-ups, while others with aggressive or metastatic forms need combinations of surgery, radiation, hormone therapy, and newer targeted drugs.

Where It Starts and How It Grows

Most prostate adenocarcinomas begin in the peripheral zone, the outer region of the gland closest to the rectum. In a histological study of 188 peripheral-zone cancers, about 90% were located in the posterior half of the gland, and tumors under roughly 2 cubic centimeters tended to stay confined to their zone of origin; only when they grew larger did some begin creeping into neighboring tissue like the transition zone.¹ This anatomical detail matters because it explains why a digital rectal exam can sometimes feel a nodule and why MRI sequences focus on the peripheral zone when looking for suspicious lesions.

The aggressiveness of the tumor is described by a grading system. Pathologists assign patterns based on how abnormal the glandular architecture looks under the microscope, then combine those into a score. The most clinically relevant system today uses five Grade Groups (1 through 5), with Grade Group 1 representing the least aggressive pattern and Grade Group 5 the most dangerous. A 2019 international consensus conference updated how pathologists should report specific architectural patterns, including a formal agreement to report the presence of invasive cribriform carcinoma and to incorporate intraductal carcinoma into grading, both of which signal worse outcomes.² One practical wrinkle: the grade assigned on a small needle biopsy sometimes underestimates the true grade found in the whole gland after surgery, a phenomenon called upgrading.³ That gap is one reason why imaging and newer biopsy techniques have become so important.

Who Is Most at Risk

Age is the single strongest risk factor; prostate adenocarcinoma is rare before 50 and increasingly common after 60. Beyond age, a systematic review found that men with at least one first-degree relative diagnosed with prostate cancer face a clearly increased risk, even when imaging and a previous biopsy came back negative. The same review found that Black men carry higher risk while Asian men carry lower risk, with most of the disparity attributable to environmental and socioeconomic factors, though genetic differences likely play a role too.⁴

On the genetic side, inherited mutations in specific DNA-repair genes raise risk substantially. BRCA2 is the most commonly implicated gene in men with metastatic disease; in one large Korean cohort, about 4.4% of men with metastatic prostate cancer carried a pathogenic BRCA2 mutation.⁵ A separate study in men of European descent who self-reported as white found that roughly 7-8% carried a pathogenic germline mutation in a DNA-repair gene, with BRCA2 again the most frequent.⁶ Another gene, HOXB13, harbors a variant (G84E) that was found roughly 20 times more often in men with prostate cancer than in controls of European descent, and was especially enriched in men with early-onset, familial disease.⁷ These findings explain why genetic testing is increasingly offered to men with aggressive or metastatic disease: finding a BRCA2 mutation, for instance, can open the door to specific targeted therapies.

Metabolic syndrome, the cluster of obesity, high blood pressure, abnormal cholesterol, and insulin resistance, has also drawn attention as a potential risk factor. Research suggests that its components are associated with higher prostate cancer incidence, particularly in men over 65, and that severe obesity in older men may compound the risk further.⁸ The suspected mechanisms involve insulin and insulin-like growth factors that promote cell growth, chronic low-grade inflammation from excess fat tissue, and reduced testosterone levels linked to obesity, which paradoxically appear to be associated with more aggressive tumors at presentation.⁹

Symptoms and When to Suspect It

Early prostate adenocarcinoma usually causes no symptoms at all. A structured review of evidence from primary care and screening studies confirmed that early-stage disease is essentially silent, and that when locally advanced cancer does produce urinary symptoms, those symptoms overlap almost completely with the ones caused by benign prostate enlargement: a weak stream, frequent urination, getting up at night.¹⁰ That overlap is exactly why urinary symptoms alone cannot confirm or rule out cancer and why blood tests and imaging play a central role in diagnosis. Bone pain, weight loss, or fatigue generally signal advanced disease that has already spread.

How It Is Diagnosed

Screening typically begins with a PSA blood test. PSA is useful but imperfect: levels can be elevated by infection, benign enlargement, or vigorous physical activity, not just cancer. When total PSA falls in the gray zone between 4 and 10 ng/mL, the ratio of free to total PSA helps sort things out. A meta-analysis of studies in that gray zone found that the free-to-total ratio had a pooled sensitivity of about 70% and a specificity of about 58% for detecting cancer.¹¹ In other words, it helps but is far from a definitive test on its own.

Newer blood and urine biomarkers improve on PSA’s limitations. Tests like the Prostate Health Index and the 4Kscore combine different PSA-related proteins with clinical information to better estimate the likelihood of clinically significant cancer. Urine-based tests such as PCA3 and SelectMDx can help distinguish high-grade tumors from low-risk ones, which is especially valuable for deciding whether a biopsy is warranted at all.¹² These tests are most helpful when PSA sits in that ambiguous gray zone and the clinical picture is uncertain.¹³

When a biopsy is needed, multiparametric MRI has reshaped the process. In a landmark trial, MRI-targeted biopsy detected clinically significant cancer in 38% of men compared with 26% for standard systematic biopsy, while simultaneously finding fewer clinically insignificant cancers that might have led to unnecessary treatment.¹⁴ MRI-ultrasound fusion biopsy can boost detection of significant cancers by up to 20% over systematic biopsy in men who have never been biopsied before, and in men with a previous negative biopsy, the vast majority of cancers found by MRI-targeted sampling turn out to be clinically significant.¹⁵ Radiologists use a standardized scoring system (PI-RADS) to rate suspicious lesions on MRI, which helps guide where the biopsy needles go.¹⁶

Staging and Figuring Out How Aggressive It Is

Once cancer is confirmed, the next step is determining how far it has spread. Traditional staging relies on PSA level, the Grade Group from the biopsy, and clinical exam findings, which are then combined into risk categories. Guidelines classify non-metastatic disease into risk groups; for example, the high-risk category can be reached by a PSA above 20, a locally advanced stage on exam, or a Grade Group of 4 or 5.¹⁷

For imaging beyond the prostate, PSMA PET/CT has increasingly replaced older scans like bone scans and CT. PSMA is a protein found on the surface of most prostate cancer cells, and radiolabeled tracers that bind to it allow whole-body imaging with better sensitivity and specificity for detecting both local spread and distant metastases compared with conventional imaging.¹⁸ An overview of multiple systematic reviews found moderate-to-high sensitivity and specificity for PSMA PET/CT in staging high-risk prostate cancer and detecting recurrence after initial treatment.¹⁹ This imaging modality is also useful for planning treatment of localized recurrence and for guiding targeted radiation to individual metastatic sites.²⁰

Treating Localized Disease

When prostate adenocarcinoma is confined to the gland and low-grade, active surveillance is often the most appropriate strategy. Rather than treating immediately, doctors monitor PSA levels, repeat imaging, and perform periodic biopsies to confirm the cancer is not progressing. Evidence supports expanding the criteria for who qualifies: men with clinical stage T2 disease, up to 60% involvement of any single biopsy core, and up to four positive cores (all Grade Group 1 with low PSA density) have shown safe outcomes on surveillance.²¹ Active surveillance avoids the side effects of treatment while keeping a safety net in place should the cancer show signs of becoming more dangerous.

For men who do need surgery, radical prostatectomy removes the entire prostate gland. The main debate in recent years has been between open and robot-assisted approaches. A large Swedish trial found that at two years, robot-assisted surgery showed a modest advantage in erectile function recovery compared with open surgery, while rates of urinary incontinence and cancer recurrence were similar between the two approaches.²² A related analysis from the same trial noted that the robotic approach facilitated easier identification of the nerve bundles that control erection, though open surgeons had lower rates of positive surgical margins in organ-confined disease, creating a real trade-off between functional and oncological outcomes.²³

Radiation therapy is the other major curative option. Conventional external-beam radiation has been joined by stereotactic body radiation therapy (SBRT), which delivers high doses in just a handful of sessions. Randomized trials have found SBRT to be noninferior to longer conventional courses for low- and intermediate-risk disease. For high-risk disease, brachytherapy, where radioactive seeds or sources are placed directly inside the prostate, has shown superiority over external-beam radiation alone when used as a boost.²⁴

Focal Therapy

A newer and still investigational middle ground between surveillance and whole-gland treatment is focal therapy, which aims to destroy only the cancerous area within the prostate using energy sources like high-intensity focused ultrasound, cryotherapy, or laser ablation. The appeal is obvious: targeting the tumor while sparing the nerves and sphincter could dramatically reduce urinary and sexual side effects.²⁵ The European Association of Urology, however, still considers focal therapy investigational. The main concerns are that prostate cancer is often multifocal, meaning additional cancer foci may lurk in untreated tissue, and current imaging cannot yet reliably identify all foci. Most published series report results for low-risk disease with relatively short follow-up.²⁶ Focal therapy is promising for the right patient, but it is not yet a proven standard of care.

Treating Advanced and Metastatic Disease

Prostate adenocarcinoma depends on male hormones (androgens) for growth, and the backbone of systemic treatment for advanced disease is androgen deprivation therapy (ADT), which lowers testosterone to very low levels. This approach has been used for over 75 years, and it remains effective, but the cancer almost invariably adapts. Within roughly two to three years, most tumors find ways to grow despite castrate-level testosterone, a state called castration-resistant prostate cancer.²⁷

The modern standard for metastatic disease that still responds to hormone manipulation is to combine ADT with a next-generation androgen-receptor-targeting drug such as enzalutamide or abiraterone from the outset.²⁸ These drugs work by either blocking the androgen receptor more completely (enzalutamide) or shutting down androgen production within tumors and adrenal glands (abiraterone). Even after resistance develops, these agents can still be sequenced: a European study of men who had progressed on abiraterone found that switching to enzalutamide yielded a median time without radiographic progression of about eight months.²⁹

One important predictor of whether these drugs will work is a molecule called AR-V7, a shortened version of the androgen receptor that is always active regardless of hormone levels. In a study that tested circulating tumor cells for AR-V7, none of the AR-V7-positive patients responded to enzalutamide or abiraterone, compared with response rates above 50% in AR-V7-negative men. AR-V7-positive patients also had dramatically shorter survival.³⁰ AR-V7 testing is not yet routine everywhere, but it represents a shift toward biomarker-driven treatment decisions in advanced prostate cancer.

Targeted Therapy for DNA-Repair Mutations

About a quarter of men with advanced prostate cancer carry mutations in genes involved in repairing damaged DNA, such as BRCA2, ATM, and others. These mutations make tumors vulnerable to a class of drugs called PARP inhibitors, which block a backup repair pathway the cancer cells rely on.³¹ The landmark PROfound trial showed that olaparib, a PARP inhibitor, roughly doubled the time before the cancer progressed compared with a new hormonal agent in men whose tumors had these mutations, with a median progression-free survival of about 7.4 months versus 3.6 months.³² An earlier proof-of-concept study found an especially striking result: among men whose tumors harbored confirmed DNA-repair gene defects, 88% responded to olaparib, with all seven patients carrying BRCA2 loss showing a response.³³

Several PARP inhibitor combinations are now approved: olaparib with abiraterone, niraparib with abiraterone, and talazoparib with enzalutamide, each with different approved biomarker requirements. These developments make genetic testing of the tumor, and sometimes the patient’s own germline DNA, a practical necessity for men with advanced disease.

Radioligand Therapy

One of the most significant recent advances is lutetium-177 PSMA radioligand therapy, which uses a radioactive compound that binds to the PSMA protein on cancer cells and delivers targeted radiation directly to tumors wherever they are in the body. The VISION trial demonstrated that adding lutetium-177-PSMA-617 to standard care extended median overall survival from about 11.3 months to 15.3 months in men with metastatic castration-resistant disease who had already progressed on other treatments.³⁴ The treatment has a favorable safety profile, with manageable side effects including dry mouth and mild drops in blood counts.³⁵ Ongoing research is exploring whether radioligand therapy might be even more effective when used earlier in the disease course, before chemotherapy. One retrospective study found more favorable progression-free and overall survival outcomes in chemotherapy-naive patients who received lutetium-PSMA therapy compared with those who received another hormonal agent or docetaxel chemotherapy.³⁶

Life After Treatment

Surviving prostate adenocarcinoma is increasingly common, which means more men live with the long-term consequences of treatment. The three main domains affected are urinary function, bowel function, and sexual function. A study comparing long-term prostate cancer survivors who had received radiation plus extended hormone therapy with age-matched men from the general population found that roughly 10-15% of survivors reported significant urinary or bowel problems, rates that were two to three times higher than in their peers. Sexual problems affected about half of survivors. Encouragingly, the same study found that overall quality of life for long-term survivors was similar to that of non-irradiated men of the same age, suggesting that most men adapt well.³⁷

The psychological dimension is often underappreciated. Anxiety about recurrence, coping with changes in sexual identity and intimacy, and the fatigue associated with hormone therapy all take a toll. Older men, who make up the majority of patients, may also be dealing with other chronic conditions and social isolation, compounding the emotional burden. Structured psychological support, including cognitive behavioral strategies and peer support groups, has shown benefit for managing these challenges, though access varies widely depending on where a man receives care.

How Treatment Is Changing

The treatment landscape for prostate adenocarcinoma has shifted dramatically in the past decade, and the pace of change is accelerating. The combination of better imaging (MRI and PSMA PET/CT) with better biomarkers (liquid biopsy tests, genetic profiling) means that today’s patients are more precisely diagnosed and staged than ever before. At the same time, the therapeutic toolkit has expanded from a handful of options to a layered system where biomarker results guide which drug or combination is likely to work best for a given patient. PARP inhibitors for men with DNA-repair gene mutations, radioligand therapy targeting PSMA-positive tumors, and AR-V7 testing to predict resistance to hormonal agents all represent steps toward truly personalized treatment. For men diagnosed with localized disease, the broadening of active surveillance criteria and the refinement of MRI-targeted biopsy are reducing overtreatment, arguably one of the most significant shifts in how this cancer is managed day to day.